European Commission authorises fifth safe and effective vaccine against COVID-19

By European Commission

European Commission authorises fifth safe and effective vaccine against COVID-19

The European Commission has granted a conditional marketing authorization (CMA) for the COVID‑19 vaccine Nuvaxovid, developed by Novavax, the fifth COVID-19 vaccine authorized in the EU.

This authorization follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness, and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.

The President of the European Commission, Ursula von der Leyen, said: “At a time where the Omicron variant is rapidly spreading, and where we need to step up vaccination and the administration of boosters, I am particularly pleased with today’s authorization of the Novavax vaccine. This is the fifth safe and effective vaccine of our vaccine portfolio, offering welcome additional protection to the European citizen against the pandemic. May this authorization offer a strong encouragement to everyone who has not yet been vaccinated or boosted, that now is the time to do so.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: “We add a fifth vaccine to our portfolio of safe and effective vaccines. This is our first protein-based vaccine, which shows promising results against COVID-19. Vaccination and boosting to increase protection against COVID-19 is more important than ever if we are to stem the wave of infections and counter the emergence and spread of new variants. We are offering yet another safe and effective vaccine to our citizens, alongside a renewed call to vaccinate, vaccinate, vaccinate!”

On the basis of EMA’s positive opinion, the Commission has verified all elements supporting the marketing authorization and consulted the Member States before granting the conditional marketing authorization.

Next steps

The Commission signed the contract with Novavax on 4 August 2021. With the conditional market authorization, Novavax will be able to deliver up to 100 million of their COVID-19 vaccine to the EU starting in the first quarter of 2022. The contract allows the Member States to purchase an additional 100 million doses over the course of 2022 and 2023. The first doses are expected to arrive in the first months of 2022 and for this first quarter, Member States have ordered around 27 million doses. This will add to the total amount of 2.4 billion of the vaccine by BioNTech/Pfizer, 460 million doses of the vaccine by Moderna, 400 million by AstraZeneca as well as 400 million doses by Janssen.